William A. Pastor

William A. Pastor

Auto-generated profile, based on publicly available information

William A. Pastor

Department of Biochemistry, Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
XLXiaodong Liu
Xiaodong Liu
JOJohn F. Ouyang
John F. Ouyang
FRFernando J. Rossello
Fernando J. Rossello
JTJia Ping Tan
Jia Ping Tan
KDKathryn C. Davidson
Kathryn C. Davidson
JPJose M. Polo
Jose M. Polo

1 July 2020 in Stem Cell Reports
Verified
Journal Article
Open access
JCJessica K. Cinkornpumin
Jessica K. Cinkornpumin
SKSin Young Kwon
Sin Young Kwon
YGYixin Guo
Yixin Guo
IHIshtiaque Hossain
Ishtiaque Hossain
JSJacinthe Sirois
Jacinthe Sirois
WPWilliam A. Pastor
William A. Pastor
Human embryonic stem cells (hESCs) readily differentiate to somatic or germ lineages but have impaired ability to form extra-embryonic lineages such as placenta or yolk sac. Here, we demonstrate that naive hESCs can be converted into cells that exhibit the cellular and molecular phenotypes of human trophoblast stem cells (hTSCs) derived from human placenta or blastocyst. The resulting "transdifferentiated" hTSCs show reactivation of core placental genes, acquisition of a placenta-like methylome, and the ability to differentiate to extravillous trophoblasts and syncytiotrophoblasts. Modest differences are observed between transdifferentiated and placental hTSCs, most notably in the expression of certain imprinted loci. These results suggest that naive hESCs can differentiate to extra-embryonic lineage and demonstrate a new way of modeling human trophoblast specification and placental methylome establishment.

15 December 2021 in Epigenetics & Chromatin
Verified
Journal Article
Open access
PDF file
NPNathalia Azevedo Portilho
Nathalia Azevedo Portilho
DSDeepak Saini
Deepak Saini
IHIshtiaque Hossain
Ishtiaque Hossain
JSJacinthe Sirois
Jacinthe Sirois
CMChristopher Moraes
Christopher Moraes
WPWilliam A. Pastor
William A. Pastor
Background: DNA methylation plays an important role in regulating gene expression in mammals. The covalent DNMT1 inhibitors 5-azacytidine and decitabine are widely used in research to reduce DNA methylation levels, but they impart severe cytotoxicity which limits their demethylation capability and confounds interpretation of experiments. Recently, a non-covalent inhibitor of DNMT1 called GSK-3484862 was developed by GlaxoSmithKline. We sought to determine whether GSK-3484862 can induce demethylation more effectively than 5-azanucleosides. Murine embryonic stem cells (mESCs) are an ideal cell type in which to conduct such experiments, as they have a high degree of DNA methylation but tolerate dramatic methylation loss. Results: We determined the cytotoxicity and optimal concentration of GSK-3484862 by treating wild-type (WT) or Dnmt1/3a/3b triple knockout (TKO) mESC with different concentrations of the compound, which was obtained from two commercial sources. Concentrations of 10 µM or below were readily tolerated for 14 days of culture. Known DNA methylation targets such as germline genes and GLN-family transposons were upregulated within 2 days of the start of GSK-3484862 treatment. By contrast, 5-azacytidine and decitabine induced weaker upregulation of methylated genes and extensive cell death. Whole-genome bisulfite sequencing showed that treatment with GSK-3484862 induced dramatic DNA methylation loss, with global CpG methylation levels falling from near 70% in WT mESC to less than 18% after 6 days of treatment with GSK-3484862. The treated cells showed a methylation level and pattern similar to that observed in Dnmt1-deficient mESCs. Conclusions: GSK-3484862 mediates striking demethylation in mESCs with minimal non-specific toxicity.

7 November 2022 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
JRJanane F. Rahbani
Janane F. Rahbani
Charlotte ScholtesCharlotte Scholtes
Charlotte Scholtes
DLDamien M. Lagarde
Damien M. Lagarde
MHMohammed F. Hussain
Mohammed F. Hussain
ARAnna Roesler
Anna Roesler
LKLawrence Kazak
Lawrence Kazak
Noradrenaline (NA) regulates cold-stimulated adipocyte thermogenesis1. Aside from cAMP signalling downstream of β-adrenergic receptor activation, how NA promotes thermogenic output is still not fully understood. Here, we show that coordinated α1-adrenergic receptor (AR) and β3-AR signalling induces the expression of thermogenic genes of the futile creatine cycle2,3, and that early B cell factors, oestrogen-related receptors and PGC1α are required for this response in vivo. NA triggers physical and functional coupling between the α1-AR subtype (ADRA1A) and Gαq to promote adipocyte thermogenesis in a manner that is dependent on the effector proteins of the futile creatine cycle, creatine kinase B and tissue-non-specific alkaline phosphatase. Combined Gαq and Gαs signalling selectively in adipocytes promotes a continual rise in whole-body energy expenditure, and creatine kinase B is required for this effect. Thus, the ADRA1A–Gαq–futile creatine cycle axis is a key regulator of facultative and adaptive thermogenesis.

3 July 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
AGAdda-Lee Graham-Paquin
Adda-Lee Graham-Paquin
DSDeepak Saini
Deepak Saini
JSJacinthe Sirois
Jacinthe Sirois
IHIshtiaque Hossain
Ishtiaque Hossain
MKMegan S Katz
Megan S Katz
WPWilliam A Pastor
William A Pastor
ZMYM2 is a transcriptional repressor whose role in development is largely unexplored. We found that Zmym2−/− mice show embryonic lethality by E10.5. Molecular characterization of Zmym2−/− embryos revealed two distinct defects. First, they fail to undergo DNA methylation and silencing of germline gene promoters, resulting in widespread upregulation of germline genes. Second, they fail to methylate and silence the evolutionarily youngest and most active LINE element subclasses in mice. Zmym2−/− embryos show ubiquitous overexpression of LINE-1 protein as well as aberrant expression of transposon-gene fusion transcripts. ZMYM2 homes to sites of PRC1.6 and TRIM28 complex binding, mediating repression of germline genes and transposons respectively. In the absence of ZMYM2, hypermethylation of histone 3 lysine 4 occurs at target sites, creating a chromatin landscape unfavourable for establishment of DNA methylation. ZMYM2−/− human embryonic stem cells also show aberrant upregulation and demethylation of young LINE elements, indicating a conserved role in repression of active transposons. ZMYM2 is thus an important new factor in DNA methylation patterning in early embryonic development.

2 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
IHIshtiaque Hossain
Ishtiaque Hossain
PPPierre Priam
Pierre Priam
SRSofia C. Reynoso
Sofia C. Reynoso
SSSahil Sahni
Sahil Sahni
XZXiao X. Zhang
Xiao X. Zhang
WPWilliam A. Pastor
William A. Pastor
The primed epiblast acts as a transitional stage between the relatively homogeneous naïve epiblast and the gastrulating embryo. Its formation entails coordinated changes in regulatory circuits driven by transcription factors and epigenetic modifications. Using a multi-omic approach in human embryonic stem cell models across the spectrum of peri-implantation development, we demonstrate that the transcription factors ZIC2 and ZIC3 have overlapping but essential roles in opening primed-specific enhancers. Together, they are essential to facilitate progression to and maintain primed pluripotency. ZIC2/3 accomplish this by recruiting SWI/SNF to chromatin and loss of ZIC2/3 or degradation of SWI/SNF both prevent enhancer activation. Loss of ZIC2/3 also results in transcriptome changes consistent with perturbed Polycomb activity and a shift towards the expression of genes linked to differentiation towards the mesendoderm. Additionally, we find an intriguing dependency on the transcriptional machinery for sustained recruitment of ZIC2/3 over a subset of primed-hESC specific enhancers. Taken together, ZIC2 and ZIC3 regulate highly dynamic lineage-specific enhancers and collectively act as key regulators of human primed pluripotency.